Connect Biopharma Holdings
CNTB
15 hedge funds and large institutions have $8.4M invested in Connect Biopharma Holdings in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
2% more capital invested
Capital invested by funds: $8.22M → $8.4M (+$180K)
5.37% less ownership
Funds ownership: 18.3% → 12.93% (-5.4%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.45M |
| 2 |
Renaissance Technologies
New York
|
+$238K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$18.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$14.6K |
| 5 |
KMWM
Keudell/Morrison Wealth Management
Salem,
Oregon
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.66M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$532K |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$434K |
| 4 |
BlackRock
New York
|
-$101K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$50.7K |
CNTB Hedge Fund Activity: Q4 2023 in Review
15 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q4 2023, worth a combined $8.4M — up 2.2% from $8.22M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CNTB positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 6 trimmed.
The largest buyer was BML Capital Management, opening a new position worth an estimated $2.45M. The largest seller was RA Capital Management, cutting an estimated $4.66M.
- 15 institutional investors held Connect Biopharma Holdings (CNTB) as of Q4 2023, up from 14 in Q3 2023.
- Funds reported $8.4M of Connect Biopharma Holdings stock for Q4 2023, up 2.2% quarter-over-quarter.
- 4 funds opened new Connect Biopharma Holdings positions in Q4 2023 and 3 closed out, a net change of +1 holder.
- The largest Connect Biopharma Holdings buyer in Q4 2023 was BML Capital Management, an estimated $2.45M added.
- The largest Connect Biopharma Holdings seller in Q4 2023 was RA Capital Management, an estimated $4.66M sold.
Based on aggregated 13F filings for Q4 2023.